Drug Profile
Research programme: antiviral therapeutics - Cocrystal Pharma/Kansas State University Research Foundation
Alternative Names: Mpro protease inhibitors - Cocrystal PharmaLatest Information Update: 08 Dec 2021
Price :
$50
*
At a glance
- Originator Kansas state university research foundation
- Developer Cocrystal Pharma Inc; Kansas state university research foundation
- Class Antivirals; Small molecules
- Mechanism of Action Peptide hydrolase inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Coronavirus infections; COVID 2019 infections; Norovirus infections
Most Recent Events
- 01 Dec 2021 Cocrystal Pharma Inc plans a phase I trial for COVID-2019 infections (In volunteers) (PO), in 2022
- 01 Dec 2021 Cocrystal Pharma Inc plans a phase II trial for COVID-2019 infections (PO), in 2022
- 18 Oct 2021 Preclinical trials in Norovirus infections in USA (PO) (Cocrystal Pharma pipeline, October 2021)